News >

Bunn Discusses Future of Immunotherapy in SCLC

Jason Harris
Published: Thursday, Aug 30, 2018

Paul A. Bunn Jr, MD

Paul A. Bunn Jr, MD
For the first time in decades, physicians treating small cell lung cancer (SCLC) are getting new tools in their armamentarium, said Paul A. Bunn Jr, MD.

in Lung Cancer, discussed the potential for new agents to treat SCLC, the challenges involved in treating this population, and the ongoing search for biomarkers to guide treatment decisions.

OncLive: Could you provide an overview on the current state of research in SCLC?

Bunn: The main immunotherapeutic agents being studied now are checkpoint inhibitors—antibodies that bond to either PD-1 or PD-L1. Since they bind to that interaction, one of the biomarkers that has been explored is PD-L1 expression. In some cancers, such as non–small cell lung cancer (NSCLC), that's been a decent biomarker. One of the issues in SCLC is that these tumors tend to have pretty low PD-L1 expression. Therefore, one of the major issues is, just like in NSCLC, is there a better biomarker?
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication